FDA Issues Tamiflu Precautions Update

Lee Coleman

Contributor

0 CommentsPrint ArticleSubscribe

Roche Laboratories and the FDA notified healthcare professionals of new revisions to the Precautions/Neuropsychiatric Events and Patient Information sections of prescribing for Tamiflu. Postmarketing reports have been of self injury and delirium with Tamiflu use in patients with influenza. Pediatric patients were primarily the ones reported. Patients with influenza should be closely monitored throughout the treatment period for signs of abnormal behavior. A healthcare professional should be contacted immediately if any signs of unusual behavior occur. Tamiflu is indicated for the treatment of uncomplicated acute illness due to influenza infection.